Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
porcine circovirus recombinant virus (CPCV) 1-2, inactivated
Zoetis Belgium SA
QI09AA07
adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets
Pigs (piglets)
Immunologicals
Active immunisation of pigs over the age of three weeks against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with PCV2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with post-weaning multisystemic wasting syndrome.
Revision: 13
Withdrawn
2009-07-24
Medicinal product no longer authorised 16 B. PACKAGE LEAFLET Medicinal product no longer authorised 17 PACKAGE LEAFLET: SUVAXYN PCV SUSPENSION FOR INJECTION FOR PIGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM Manufacturer responsible for batch release: Zoetis Manufacturing & Research Spain, S.L. Ctra. Camprodón s/n "la Riba" 17813 Vall de Bianya Girona SPAIN 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn PCV suspension for injection for pigs 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose of 2 ml contains: ACTIVE SUBSTANCE: Inactivated recombinant Porcine Circovirus type 1 expressing the Porcine Circovirus type 2 ORF2 protein 1.6 ≤ RP* ≤ 5.3 ADJUVANTS: Sulfolipo-cyclodextrin (SLCD) 4 mg Squalane 64 mg EXCIPIENTS: Thiomersal 0.1 mg * Relative Potency unit determined by ELISA antigen quantification ( _in vitro_ potency test) compared to a reference vaccine. A milky white to pink opaque liquid, free from visible particles 4. INDICATION(S) Active immunisation of pigs over the age of 3 weeks against Porcine Circovirus Type 2 (PCV2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with PCV2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with Post-Weaning Multisystemic Wasting Syndrome (PMWS). Onset of immunity: from 3 weeks post-vaccination. Duration of immunity: 19 weeks post-vaccination Medicinal product no longer authorised 18 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS A transient increase in body temperature (up to 1.7 °C) is very common during the first 24 hours after vaccination. This resolves spontaneously within 48 hours without treatment. Local tissue reactions in the form of swelling at the injection site are very common and may last for up to 26 days. The Aqra d-dokument sħiħ
Medicinal product no longer authorised 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn PCV suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml contains: ACTIVE SUBSTANCE: Inactivated recombinant Porcine Circovirus type 1 expressing the Porcine Circovirus type 2 ORF2 protein 1.6 ≤ RP* ≤ 5.3 ADJUVANTS: Sulfolipo-cyclodextrin (SLCD) 4 mg Squalane 64 mg EXCIPIENTS: Thiomersal 0.1 mg * Relative Potency unit determined by ELISA antigen quantification ( _in vitro_ potency test) compared to a reference vaccine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection A milky white to pink opaque liquid, free from visible particles 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs (piglets) from 3 weeks of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of pigs over the age of 3 weeks against Porcine Circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with PCV2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with Post-Weaning Multisystemic Wasting Syndrome (PMWS). Onset of immunity: from 3 weeks post-vaccination. Duration of immunity: 19 weeks post-vaccination. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate healthy animals only. Do not use in breeding boars. Medicinal product no longer authorised 3 The benefit of the vaccination of pigs with very high levels of maternally-derived antibodies, e.g. due to vaccination of their mothers, has not been demonstrated. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Avoid stress in the animals before and after the time of vaccination. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical Aqra d-dokument sħiħ